Genetic Technologies (GENE) rises 21% premarket after saying it has executed an agreement with a...


Genetic Technologies (GENE) rises 21% premarket after saying it has executed an agreement with a fifth PPO, allowing the company's BREVAGen test to be adjudicated "in network," where reimbursement is 25% higher and collection times are "materially shorter." (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs